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Following up on the Consensus Conference on high-grade malignant salivary gland tumours (HGMSGT) in
adult patients in Brescia, Italia, in October 2014, we review the current imaging modalities for diagnosing
and staging these rare tumours. The advantages of functional MR imaging techniques such as diffusion
weighted imaging (DWI) and dynamic contrast-enhanced MR imaging (DCEMRI) in comparison with tra-
ditional MRI will be outlined. The limited role of 18FDG-PET CT and fMRI will be addressed. Finally, in
view of new experimental treatment options, we will discuss the role of imaging during follow-up.
 2016 Elsevier Ltd. All rights reserved.Introduction
During the Consensus Conference on Salivary Gland Tumours in
Brescia, Italia, October 2014, new diagnostic developments in
many different fields of clinical research were presented and
discussed.
This paper will review current imaging modalities which may
contribute to better diagnosis and staging of malignant salivary
gland tumours. As in the past, studies on new imaging techniques
are hampered by small numbers, due to the rarety of the disease,
and by ongoing new developments in imaging, resulting in a pau-
city of data.Epidemiology
Salivary gland tumours are rare, accounting for about 2–6.5% of
all head and neck tumours and for about 0.5% of all malignancies.By far the most common location is the parotid gland, with about
70% of tumours arising at this site, followed by – in decreasing
order – the submandibular gland, the minor salivary glands and
the sublingual gland. Most tumours are benign pleomorphic ade-
nomas (about 65% of all parotid tumours), followed by adenolym-
phoma or Warthin’s tumour (15–20% of all parotid tumours) [1,2].
Malignant epithelial salivary gland tumours are uncommon: the
annual incidence rate worldwide is less than 2–3 per 100.000
[3,4]. They account for about 20–30% of parotid tumours, approxi-
mately 40% of submandibular gland tumours, 50% of minor salivary
gland tumours and 90% of sublingual gland tumours. If left
untreated, in 6.5% of cases (range 1.9–23.3%) benign pleomorphic
adenomas may dedifferentiate into a high-grade malignant
tumour, carcinoma-ex-pleomorphic adenoma [1,5]. Salivary gland
tumours are classified according to the World Health Organization
(WHO) histologic classification into 31 different types, of which 24
are malignant [3], making final diagnosis a challenge in many
cases. The most common low-grade salivary gland tumours are
muco-epidermoid carcinoma, adenocarcinoma not otherwise spec-
ified (NOS) and acinic cell carcinoma. Many other histologic types
do occur, but they are rare [6]. Adenoid cystic carcinoma (ACC) is a
high-grade malignant salivary gland tumour (HGMSGT) and is
158 N. Freling et al. / Oral Oncology 60 (2016) 157–166reported as the second most common or fifth most commonmalig-
nant tumour by different authors [7,1]. Although ACC are known
for their slow biological growth, they tend to have a protracted
course and final outcome is poor for all grades, with a less than
50% survival rate at 10 years [6]. High grade malignant, non-ACC
tumours of the salivary glands are rare and histologically
extremely diverse, consisting of high-grade mucoepidermoid carci-
noma, adenocarcinoma NOS, carcinoma ex pleomorphic adenoma,
myoepithelial carcinoma, anaplastic small cell carcinoma, carci-
nosarcoma, large cell undifferentiated carcinoma, small cell undif-
ferentiated carcinoma, salivary duct carcinoma and also squamous
cell carcinoma (to be differentiated from metastases of CUP).
Non-epithelial malignant tumours represent a minority of
malignant salivary gland tumours. Extranodal primary lymphoma
of the salivary glands is rare, accounting for only 5% of all extran-
odal NHL, 2% of all salivary gland tumours [8,9] and 16% of all
malignant salivary gland tumours [7,6]. Eighty percent are located
in the parotid gland. Bilateral disease is not uncommon. Mucosa-
associated lymphoma type (MALT) is the most prevalent histologic
subtype. Patients with acquired or drug-induced immunodefi-
ciency (M. Sjoegren) have an increased relative risk for developing
parotid MALT lymphoma and also for development of non-Hodgkin
lymphoma [10]. Salivary glands are secondarily involved in 1–8% of
patients with systemic high grade B-cell NHL, with 80% involving
the parotid gland [11].
Mesenchymal malignant tumours make up 1.5% of all malig-
nant salivary gland tumours [6] and include malignant schwanno-
mas, malignant fibrous histiocytomas, solitary fibrous tumours,
and rhabdomyosarcomas, among others.
Metastases make up about 10% of all malignant salivary gland
tumours. Most (80–90%) are located in the parotid gland. Eighty-
percent result from primary tumours elsewhere in the head and
neck, only 20% from infraclavicular locations [6,12].
Perineural spread (PNS) is reported in greater than 50% of cases
and is particularly common for ACC [1].
Locoregional lymph node metastases from malignant salivary
gland tumours are seen in about 10–15% of patients at presenta-
tion but are more common (>30%) in high-grade than in low-
grade salivary gland tumours [3,13]. Distant metastases occur in
about 10–50% of patients at first presentation and may be seen
in low and in high T-stages during follow-up [1,14]. In recurrent
disease lymph node and distant metastases are more frequently
observed [13].
Clinical presentation, family history, imaging and other diag-
nostic tests are sometimes required to classify a tumour as benign
or malignant and in a few equivocal cases only long time follow-up
will decide about the clinical behaviour – indolent or aggressive
[6]. Although primary surgery is the treatment of choice for sali-
vary gland tumours, curative chemo-radiation has recently become
available as a treatment modality when curative surgery (R0) is not
possible and in patients with recurrent disease [15].
The role of imaging in malignant tumours is to stage a tumour
according to the TNM classification and to assess the feasibility of
surgery, which is the primary treatment of most salivary gland
tumours. Imaging provides information about location (intra- or
extraglandular, superficial or deep to the facial nerve), local exten-
sion and invasion, the nature of a tumour, the presence of perineu-
ral spread (PNS) and nodal and/or distant metastases, all of which
affect surgical management decisions. Malignant primary salivary
gland tumours are rarely multiple or bilateral. However, bilateral,
multifocal involvement may occur in malignant lymphoma or
metastatic disease from non-salivary tumours; recurrent disease
may also present as multifocal tumour depositions. The site of ori-
gin of a salivary gland tumour determines the initial imaging tech-
nique for diagnosis. For superficial tumours within the parotid or
submandibular glands, ultrasound (US) is the preferred initialimaging technique if the lesion presents as a circumscribed mass
at clinical examination and is often combined with fine needle
aspiration cytology (FNAC). The diagnosis is usually obtained clin-
ically in cases of minor salivary gland tumours arising from the
upper aerodigestive tract mucosa.
Magnetic Resonance Imaging (MRI) is indicated in all patients in
whom a malignant tumour is suspected clinically. If the mass can-
not be depicted clearly on US or if there are signs suggesting extra-
glandular extension, additional MRI should be obtained.Imaging techniques
Ultrasound
Ultrasound (US) plays an important role in the initial diagnostic
work up of patients presenting with a superficial preauricular or
submandibular swelling. High resolution US with Doppler tech-
nique provides excellent tissue characterization, multiplanar infor-
mation and vascular pattern. US is optimal to guide fine needle
aspiration cytology. However, US is limited to superficial structures
and accuracy depends on specialist expertise [11]. A high variabil-
ity of results has been reported for US studies, with sensitivity
ranging from 62% to 84%, specificity from 88% to 96%, and accuracy
from 57% to 96% [16]. While superficial parotidectomy is the treat-
ment of choice for well-defined benign and malignant parotid
tumours, further diagnostic imaging and staging may be postponed
in some patients until final histologic diagnosis has become
available.
US offers no advantages over MRI to stage malignant primary
tumours, because deep compartments cannot be depicted and
retropharyngeal lymphadenopathy and perineural spread cannot
be assessed. While intraoral US with high-resolution small probes
is used for staging of tongue tumours, its use for staging intra-oral
minor salivary gland lesions has not been reported to the knowl-
edge of the authors.
US-guided Fine Needle Aspiration Cytology (FNAC) may provide
additional information regarding the nature of a lesion offering
useful information for the management of salivary gland tumours.
It enables more confident preoperative patient counselling and
may reduce intraoperative and/or postoperative surprises [17].
The combination of US-imaging and FNAC is debated by Bartels
et al., who found comparable results for diagnosing malignant
tumours by either technique alone (US alone or US-FNAC); they
found no advantages in combining the two diagnostic tests, neither
in terms of sensitivity, nor specificity, nor accuracy [18]; others
reported a low sensitivity of US with FNAC, for distinguishing
benign from malignant neoplasms and a high variability of results
among different facilities, studies and countries [19]. The negative
predictive value of FNAC is reported to be low (66%), thus negative
results should be treated with caution [20]. In case of failure of US-
guided FNAC, a reliable diagnosis of malignancy can be obtained by
US-guided core-needle biopsy (CNB), which has a sensitivity of 93%
and an accuracy of 98% [21]. FNAC has the lowest results in non-
neoplastic disease, where CNB may be of great value [20]. In a sys-
tematic review and meta-analysis of the literature, Witt et al.
found that complications are rare when using 18G core-needles:
mainly subclinical haematoma formation (8 in 512 procedures),
temporary facial weakness (1 in 512 procedures) [20] and fistula
formation in parotitis, not in tumours [22,23]. There have been
infrequent case reports of tumour seeding following both FNAC
and CNB, but studies investigating tumour seeding as a function
of needle diameter are lacking [20].
Thus US-FNAC has 2 main applications: first in diagnosing pri-
mary tumours and second in staging lymph node metastases.
Fig. 2. Highly malignant parotid tumour on the left in 72 yrs female, who had been
diagnosed with pleomorphic adenoma 18 yrs earlier but refused surgery at that
time. Facial nerve palsy, pain and ulcerations. Note the heterogeneous aspect, the
low T2 signal and the aggressive invasion of the masticator space (thick arrows) and
alteration of normal fat signal of the bone marrow in the left mandible (black
arrow; compare to normal right side: white arrow). Histology: carcinoma ex
pleomorphic adenoma.
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Traditional MRI: Basic spin-echo (SE) technique
MRI remains the preferred imaging modality for staging a
malignant salivary gland tumour because of its invaluable soft tis-
sue contrast, its multi-planar representation and optimal anatomic
display. Routine high-resolution multiplanar turbo spin-echo (TSE)
T1, T2 and post contrast (Gadolinium) images with fat saturation
(FS) form the basis for assessment of tumour location and loco-
regional tumour mapping [11,24–27] (Fig. 1). Due to the fatty
changes of the parotid gland in adults, most parotid tumours can
be easily depicted on non-contrast enhanced TSET1 weighted
images due to their relatively low T1 signal. Normal fat has a nat-
ural high signal on TSET1 and T2 weighted sequences, and, there-
fore, subtle infiltration into adjacent fat planes can be observed
on non-contrast enhanced SET1 weighted images. While Gadolin-
ium shortens relaxation time, thereby increasing the signal of the
enhancing tissues, fat saturation is applied after intravenous
Gadolinium to amplify the contrast difference between the
enhanced lesions and normal fat. High-resolution post-
Gadolinium sequences with fat saturation help in depicting subtle
tumour extension, but their main function is in assessing invasion
of adjacent structures and demonstrating abnormal perineural
enhancement along the facial and/or trigeminal nerves, indicating
perineural spread (PNS) [28,11,29].
Common imaging findings of HGMSGT are ill-defined borders
(Fig. 2), invasion into adjacent tissues or compartments, low T2 sig-
nal, heterogeneous enhancement, cystic changes and central
necrosis [11]. Highly malignant, fast growing tumours, such as par-
otid duct cancer, may sometimes look like a cystic tumour, due to
extensive necrosis [30]. Low-grade malignant tumours may resem-
ble benign lesions [31,28]. Lymph node metastases are more com-
monly seen in HGMSGT than in low-grade tumours. The size of aFig. 1. M, 56 yrs, pre-auricular swelling, slowly increasing in size over months. Standard
(b1000) ADC. Note the well-defined, large tumour in the superficial lobe of the left paroti
aspect, high T2 signal, heterogeneous, strong enhancement after Gadolinium. High signal
low-grade malignant disease. Histology: benign pleomorphic adenoma.malignant tumour is correlated with its high-grade or low-grade
nature and with the occurrence of distant metastases [14]:
tumours, that are clinically less than 4 cm having a better progno-
sis than tumours greater than 4 cm [1].
Selected imaging features such as cystic components or rim
enhancement have been subjected to further investigation. Kato
et al. [27] reported a series of 72 patients, presenting with 44
benign and 28 malignant parotid gland tumours. Cystic compo-
nents were seen in 22/44 (50%) benign and 22/28 (78%) malignantMRI protocol: SET1, TSET2, post Gadolinium without and with fat saturation, DWI
d gland (arrows). There is no invasion of adjacent compartments. Note the lobulated
on b1000 in combination with high signal on ADC (white circle) suggests benign or
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benign and in 12/22 of malignant tumours, whereas central cystic
areas were seen only in malignant tumours. The differences were
statistically significant (p < 0.001). Hyperintense T1 signal also
was considered a discriminative feature of benign tumours, mostly
due to haemorrhagic or proteinaceous contents or many small
cysts, whereas T2 signal did not differ significantly between the
two groups.
Sakamoto et al. [26] analysed capsule-like rim enhancement
(CLRE) on post-Gadolinium SET1 MRI of 100 patients with parotid
tumours and compared this to histologic findings. CLRE was
observed in 74 patients, in 51/66 (77%) benign and in 23/34
(67%) malignant tumours. They found that irregular thickening
and peripheral nodules within the wall were seen more commonly
in malignant tumours. The optimal cut-off value to discriminate
between benign and malignant lesions was at 1.5 mm wall thick-
ness with a sensitivity of 78%, specificity of 78% and accuracy of
78% (p < 0.001). Excluding Warthin tumours, 5/23 (22%) malignant
lesions showed a thin rim, while a thick rim was observed in 3/51
(8%) benign lesions. Warthin tumours could not be differentiated
from malignant tumours on the basis of the CLRE alone, but could
be distinguished using diffusion and/or dynamic contrast-
enhanced MRI techniques. The authors conclude, using a cut-off
wall thickness of 1.5 mm, CLRE is a valuable measurement to fur-
ther differentiate malignant from benign tumours on SET1
weighted post-Gadolinium sequences.
Perineural spread (PNS) can be observed on pre- and post-
Gadolinium sequences. Imaging features of PNS include replace-
ment of fat in neural foramina and diffuse or nodular thickening
and pathologic enhancement of the named cranial nerves
[32,29,11]. Both CT and MR can detect perineural spread (PNS),
but MR is the modality of choice due to its superb soft tissue con-
trast (Fig. 3). Regarding salivary gland tumours the most com-
monly involved nerves in early PNS are the facial (VIIth) and
trigeminal (Vth) nerves which are closest to the major salivary
glands, with the auriculo-temporal nerve serving as an important
connection. However, in extensive disease, other cranial nerves
may become involved as well. High-resolution post-contrast fat-
suppressed T1 weighted sequences are recommended [33,29].
Direct signs of nerve abnormality are detectable by this MR tech-
nique, namely the segmental nerve enhancement due to neoplastic
disruption of the blood-nerve-barrier leading to increased perme-
ability (Fig. 4). The sensitivity of MRI for PNS along cranial nerves
is greater than that of CT, ranging from 70% to 95% [34,35].
Observed limitations of MRI are the false positive findings causedFig. 3. (A and B) Axial SET1 post Gadolinium with fat saturation. Patient operated for a
recurrent tumour. Recurrent tumour in left nasal cavity (thick arrow). Perineural tumour
along its course in the pterygopalatine fossa through the round foramen into the caverno
left (B. thick arrow). No clinical symptoms related to PNS.by changes due to inflammatory or granulomatous disease, reduc-
ing specificity to about 85%; incomplete mapping of all nerves
involved – per patient – may drop the sensitivity to 20–37% [36].
Microscopic neoplastic infiltration below the resolution of MRI
technique may account for some inaccuracy of PNS mapping and
may explain the presence of skip lesions. MRI is the technique of
choice to assess intracranial PNS spread along the Vth nerve to
Meckel’s cave and cavernous sinus or along the VIIth nerve to
the geniculate ganglion. To assess direct intracranial extension
via the skull base or direct invasion of the skull base is one of
the main goals of imaging today, being of utmost importance in
planning appropriate treatment. Permeative invasion into spongi-
otic/diploic bones (mandible, skull base) maymanifest as extensive
replacement of medullary fat spaces in the absence of gross cortical
erosions. Such findings are more easily detected with MRI. The
plain SET1 sequence is by far superior to CT [37,38].
3D post-contrast volume imaging
In recent years ultrafast 3D gradient echo sequences have been
developed, providing better anatomic detail and offering multipla-
nar reconstructions. Different manufacturers have given this tech-
nique varying acronyms (e.g. VIBE, THRIVE, LAVA-FLEX, RADIANCE
for 1.5 T and 3 T systems). Multiplanar reconstructions are
obtained from a volume stack of ultra-thin (0.4–0.8 mm), isotropic,
axial images instead of performing many additional series in differ-
ent planes [39]. Flow-related artefacts are significantly reduced
compared to spin-echo techniques [40]. However, compared to
spin-echo techniques, this volumetric technique is still prone to
greater patient motion and susceptibility artefacts (e.g. from dental
works). Wu et al. [41] compared a more robust 3D fat-suppressed
technique with standard post-contrast spin-echo T1 sequences and
reported a significant improvement of tumour delineation, degree
of fat suppression, mucosal enhancement and lesion edge-
sharpness. This 3D fat-suppressed technique is very useful for
delineating subtle tumour extension to the skull base, along cranial
nerves or intracranially. These 3D sequences may also be helpful
for measuring tumour volume as an expression of treatment suc-
cess or failure. Kataoke et al. conclude that 3D VIBE is an acceptable
alternative to post contrast spin-echo T1 weighted sequences [42].
Functional MRI techniques
Diffusion weighted imaging (DWI) provides information about
the nature of a tumour, often before final histologic diagnosis hasdenoid cystic carcinoma of minor salivary glands in the nasal cavity. Presents with
spread (PNS) along the branches of the left trigeminal nerve: thickening of the V-2
us sinus (A. small arrows). Note the compression of the internal carotid artery on the
Fig. 4. (A and B) Low-grade mucoepidermoid carcinoma of left parotid gland. The tumour is located in the deep portion of the gland, shows hypointense signal on TSE T2 (A)
and quite homogeneous enhancement post contrast administration on VIBE (B). Arrows on A and B point to the irregular, though well defined, outline of the tumour. (C and D)
Ductal carcinoma of left parotid gland. The tumour shows heterogeneous signal with central necrosis on both TSE T2 (C) and post contrast VIBE (D). The whole gland is
invaded (arrows on C and D). Arrowheads on D indicate the possible course of a thickened and fuzzy left facial nerve. Compare with the normal one in a similar position
within the right gland (curved arrow on D).
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dom translational motion of molecules (also called Brownian
motion) that results from the thermal energy carried by these
molecules – a physical process that was well characterized by
Einstein [43]. Free water molecules normally contribute to signal
formation in MRI. Diffusion weighted imaging (DWI) is a technique
that expresses freedom of motion of water molecules in intercellu-
lar spaces and relates to cellular density of tissues. Motion is
reduced in highly cellular tissues and very thick fluids (abscess)
but in clear fluids (cysts) no motion restriction is observed. Signal
intensity is plotted against resonance time at b0 (at the start) and
b1000 (at the latest) and apparent diffusion coefficient (ADC) val-
ues can be calculated [44]. Highly cellular tumours contain few
free water molecules in the intercellular spaces, which results in
diffusion restriction that can be seen as a high signal spot on the
b1000 images and a corresponding area of low signal on the ADC
map. Low-grade tumours normally show low signal on b1000
images and relatively high ADC values representing a low degree
of diffusion restriction, findings that overlap with benign lesions.
Most high-grade malignant tumours show a high degree of diffu-
sion restriction, overlapping with benign tumours, where malig-
nant lymphoma is characterized by extremely low ADC values,
but in all series overlap exists between malignant and Warthin
tumours, due to their high cellularity [45,8,46].
In 2009, Habermann et al. [47] reported on a larger series
of 136 patients, 87 with a benign and 49 with an epithelial
malignant parotid tumour. Mean ADC values for malignant
tumours varied between 0.79 and 1.10  103/mm2/s, which was
significantly lower than the ADC values of pleomorphic adenomas
(2.09  103/mm2/s). However, there was overlap, with Warthin
tumours having a mean ADC value of 0.89  103/mm2/s. They
concluded that due to overlapping ADC values between benign
and malignant tumours and overlap within the groups, diagnosis
on the basis of ADC maps alone is not possible.
In view of these data, and considering the short duration of DWI
sequences, there is a strong tendency to incorporate DWI in rou-
tine MR imaging protocols and to use ADC maps as a non-
invasive indicator of malignancy [46].Dynamic Contrast-Enhanced MRI (DCE-MRI) is a technique in
which the degree of tumour enhancement is plotted against time.
Time-to-peak enhancement (T-peak) and a washout ratio (WR) are
useful parameters to differentiate benign from malignant tumours.
Yabuuchi et al. [48] reported on DCEMRI in 29 patients (33 salivary
gland tumours) and proposed a classification according to 4
different time intensity curves (TIC): type A (T-peak of >120 s
without WR) representing benign disease, type B (T-peak > 120 s
and WR > 30%) representing Whartin’s tumours, type-C
(T-peak < 120 s and a WR < 30%) representing malignant and
benign tumours and type-D, a flat line, representing cysts. Most
malignant tumours showed a type-C curve, but a small number
showed a type-B curve. When type A, B and D are considered
benign and type C malignant, a high sensitivity (91%) and speci-
ficity (91%) for differentiating between benign and malignant
tumours was found, but overlap existed in type-B and type C
lesions, consistent with other studies [49,50]. Yabuuchi et al. [25]
obtained better results combining DCEMRI with ADC maps in a
series of 50 lesions (14 malignant, 36 benign) with sensitivity
increasing from 71% to 86%, specificity from 86% to 97%, accuracy
from 82% to 92%, PPV from 67% to 92% and NPV from 89% to
94%. Espinoza et al. [51] proposed an algorithm for MRI interpreta-
tion using diffusion and perfusion (DCEMRI). Using T1 signal and
perfusion curves, they were able to single out Warthin tumours
from other tumours. T2 signal, ADC maps with cut-off values <1,
1–1.3, >1.3  103/mm2/s, and perfusion curves were used to
separate benign from malignant tumours.
For lesions, that are suspected of being malignant, adding ADC
and DCE MRI is an invaluable tool to obtain a correct diagnosis
before surgery.Intravoxel incoherent motion (IVIM) MRI
Sumi et al. [40] reported on a series of 31 epithelial salivary
gland tumours, 20 benign and 11 malignant. They used an MRI
technique called IVIM, in which diffusion and perfusion data are
integrated [52]. They showed good results for discriminating
162 N. Freling et al. / Oral Oncology 60 (2016) 157–166Warthin tumours from pleomorphic adenomas and benign from
malignant tumours. They conclude that pixel-based ADC and DCE
series can eliminate artefacts from heterogeneous tumours and
therefore effectively discriminate benign from malignant salivary
gland tumours.
Functional MRI (fMRI)
Although research has been done in applying functional MRI
(fMRI) techniques (diffusion tensor fiber tractography) on the large
cranial nerves (Vth, IInd), this technique has not yet become rou-
tine in daily practice [53]. As yet, fMRI has no clinical relevance
for the staging of primary malignant salivary tumours.
MR-spectroscopy
A recent study suggests that MR spectroscopy may differentiate
benign from malignant salivary gland tumours as well as distin-
guishing Warthin’s tumour from pleomorphic adenoma. However,
its role in routine clinical practice is not well established [54,11].Contrast-enhanced computer tomography (CECT)
Contrast-enhanced CT (CECT) is requested in patients in whom
MRI is contra-indicated (e.g. cardiac pacemaker, claustrophobia,
ferrometallic prostheses or corpora aliena) or may serve as an addi-
tional examination when MRI has questionable findings regarding
bony structures of the skull base, orbit or mandible. Thin slices
(0.6–1.0 mm) and multiplanar reconstructed images of the head
and neck are routinely obtained using bone and soft tissue algo-
rithms. However, soft tissue detail is inferior compared to MRI
and perineural tumour extension may only be appreciated in cases
of asymmetry of skull base foramina, which are caused by thicken-
ing of the nerve and erosion of the bony canal. Advantages of CECT
over MRI are, that the examination is of much shorter duration,
and, if necessary, the image volume can be extended to includeFig. 5. (A–H). (A and B) Recurrent adenoid cystic carcinoma of minor salivary gland afte
and grows sub-mucosally (arrows in A). The signal is moderately hyperintense on TSE T2
C: on follow-up MR, 7 months after salvage naso-endoscopic resection, a very small nodul
occluded via endovascular embolization). D: further growth of recurrent tumour is observ
shows greater enhancement (arrows on E and F) and abnormal signal on b1000 (arrowsthe lungs and the abdomen. However, intravenous injection of iod-
inated contrast can cause allergic reactions in some patients and
contrast nephropathy has also been reported after CECT in patients
at risk [55,56]. Therefore patients should be screened for the risk of
contrast-allergy and/or contrast-induced nephropathy by assessing
renal function and related risk factors before the examination.
These complications are observed in a much smaller number of
patients after injection of Gadolinium for MRI examination [57].18FDG-PET CT/18FDG PET-MRI
18FDG PET-CT
Salivary gland tumours are an uncommon clinical indication for
18FDG PET/CT and published data are still limited and mainly based
on the use of 18Fluorodeoxyglucose (FDG) as a metabolic imaging
radiotracer. 18FDG PET/CT is not useful to discriminate between
benign and malignant salivary gland tumours because benign
tumours, such as Warthin’s tumour, may also show high glucose
metabolism [58]. Distant metastases at presentation are reported
in 23% of patients with a low-grade tumour compared to 36% in
patients with a high-grade malignant tumour [14]. The role of
18FDG PET/CT in the initial staging of salivary gland tumours is cur-
rently controversial. However, early detection of distant metas-
tases is one of the advantages of 18FDG PET/CT and recent studies
have demonstrated that this imaging modality has a significant
effect on the management of patients with high-grade malignant
salivary gland tumours, in whom distant metastases are seen more
frequently [59–63]. 18FDG PET/CT is not recommended for the rou-
tine evaluation of low-grade malignant tumours, due to their low-
avidity for 18FDG [64]. In malignant tumours with slow develop-
ment but tendency for local invasion and final poor prognosis,
the use of 11C-methionine PET/CT might be considered. Methionine
is a neutral aminoacid that plays a key role in cancer cell metabo-
lism, and its uptake is often enhanced, even in tumours with low
glucose metabolism. A recent publication suggests that PET imag-
ing with this radiotracer could be useful for selecting an optimallyr chemo-radiation therapy. The tumour arises from the left wall of the nasopharynx
(A) and shows homogeneous enhancement after contrast agent administration (B).
e (arrow) is detected at the left foramen lacerum (the left internal carotid artery was
ed at the second follow-up, 10 months after salvage surgery (arrow). The recurrence
on G and H) than surrounding tissues both at 7 and 10 months.
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adenoid cystic carcinomas of the head and neck. The authors
demonstrated that high residual post-radiotherapy tumour uptake
was a significant factor for predicting cancer recurrence, and they
speculated that this information might be used to select those
patients deserving a strict short-term follow-up and/or active com-
bination of other treatments [65]. The major limitation of these
tracers is that, unfortunately, their use is restricted to PET centers
with in-house cyclotron and radiochemistry laboratories because
of the short half-life of 11C.
18FDG PET-MRI is a new imaging technique combining func-
tional imaging with anatomic information. This is a highly sophis-
ticated and complex technique [66,67]. As of now no clinically
applicable results use have been published for patients with sali-
vary gland tumours.Follow-UP – introduction
After curative treatment for high-grade malignant salivary
gland tumours (HGMSGT) clinical examination is impeded by
altered anatomy and fibrosis. Recurrences, especially within the
deep compartments of the face, and perineural spread may go
unnoticed clinically at its earliest stage (Fig. 5). Seventy percent
of recurrences of HGMSGT are seen within 3 years of treatmentFig. 6. (A–D) 18FDG-PET CT in recurrent adenoid cystic carcinoma. Postoperative changes
(C and D). Large FDG-avid recurrent tumour at the medial border of the resection area ([3,4]. In a large study of 565 patients with salivary gland cancer
Terhaard reported 13% local recurrences (Fig. 6), 22% regional
recurrences and 33% distant metastases during a follow-up period
of 10 years [13]. Distant metastases are reported in >50% by others
in smaller series [68,60] and are most commonly seen in high
grade ACC, adenocarcinoma NOS and carcinoma ex pleomorphic
adenoma [3]. Up to 90% of distant metastases are located within
the lungs (Fig. 7), 15% in the bones and 5% in liver, brain or other
sites (skin). Follow-up periods are reported from 3 to 10 years or
lifelong [3,4,69]. Prognosis for any treated patient with progressing
or relapsing disease is poor, regardless of cell type or stage [6]. The
efforts in surveillance should focus in particular on recurrences
whose detection may have clinical consequences, i.e. that are still
treatable with a curative intention [3,4,69].Imaging during follow-up
Ultrasound
Ultrasound (US) is a quick means to differentiate solid from cys-
tic lesions in the superficial areas of the head and neck. US guided
FNAC may help establishing the diagnosis of recurrent disease or
non-malignant complications. However, US has a limited contribu-
tion because deep compartments cannot be addressed.with fat flap on the right (arrow). Non-enhanced CT images (A and B) and FDG-PET
arrows). Large submandibular metastastic lymph node on the right (arrow).
Fig. 7. (FC) 18FDG-PET CT: multiple, FDG-avid lungmetastases at presentation in a patient with adenoid cystic carcinoma.
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With the rapid development of cross sectional imaging tech-
niques (DWI-ADC, DCE-MRI) and the increasing availability of
MRI and 18FDG PET/CT, a baseline imaging study (MRI or CECT) is
recommended by some authors [3] to facilitate early recognition
of recurrent disease during follow-up, but there are no evidence-
based studies to support this strategy. Extensive anatomic changes
are commonly observed after surgery and/or radiation therapy.
A baseline study at 3 months after completion of therapy can serve
as an invaluable road map for early detection of recurrent tumour;
the level of confidence to demonstrate or exclude recurrent disease
is higher than without a comparable baseline examination.
Although different authors have demonstrated the value of post-
treatment baseline studies for squamous head and neck cancer
[70], to the knowledge of the authors no such study for HGMSGT
is available as yet. MRI, with intravenous Gadolinium, is advised
for loco-regional assessment due to its excellent depiction of the
soft tissues. Diffusion weighted imaging may be helpful in moni-
toring treatment [71,46] and in identifying recurrent disease, as
has been reported for squamous cell cancers of the head and neck.
MRI with intravenous contrast is the only way to demonstrate per-
ineural spread along named cranial nerves, which is more often
seen in recurrences of high-grade malignant salivary tumours.
18FDG-PET/CT
Although 18FDG-PET/CT is reported as having a high diagnostic
contribution at initial staging with a change of treatment planning
in up to 15–25% of patients [58,3] recent papers do not demon-
strate a significant contribution during surveillance, due to falsenegative and false positive results [62,63,72,58]. However, 18FDG
PET/CT is superior to other cross-sectional imaging techniques to
demonstrate (occult) distant metastases and/or second primary
tumours [3]. Espinoza et al. [51] suggest that the best technique
for detecting recurrences appears to be 18FDG-PETCT combined
with DCE-MRI, and that a new rise in tissue blood flow (TBF) after
radiochemotherapy could differentiate between recurrent disease
and non-specific post-treatment changes. But their preliminary
results should be confirmed by larger studies. There is no consen-
sus on the necessity or the frequency of routine imaging during
follow-up (chest X-ray, chest CT, MRI, DWI-MRI, 18FDG PET/CT)
and the costs are considered high [69,73,74]. There is no
evidence-based study that favours routine – yearly – long-term
imaging follow-up in patients with HGMSGT. Although only pallia-
tive treatment can be offered in patients with a large tumour load,
metastasectomy in oligometastatic disease, e.g. solitary lung
metastasis in ACC, can improve survival in some selected patients,
but due to the small numbers studied, the results of this strategy
remain difficult to assess statistically. However, during the last
Consensus Meeting on HGMSGT in Brescia, October 2014, it was
suggested that follow-up CT of the chest is preferred to chest
X-ray in patients who may benefit from chemotherapy, so as to
better stage the lung nodules and follow progression or regression
of disease during and after experimental medical treatment. While
most recurrences of HGMSGT are seen within 2 years from primary
diagnosis, this seems a reasonable and not excessively costly strat-
egy. When loco-regional recurrence and/or distant metastases are
clinically suspected, a wide spectrum of imaging techniques is
used by different authors: ultrasound with FNAC is recommended
by Digonnet et al. [3]. But Gillespie et al. [4] advocate MRI with
Gadolinium or contrast-enhanced CT, or 18FDG PET/CT in patients
N. Freling et al. / Oral Oncology 60 (2016) 157–166 165who have a biopsy-proved recurrence. No evidence-based results
are available regarding the usefulness of these different strategies,
which are mainly inspired by local routine, availability and
experience.
Conclusions
MRI is the most appropriate imaging technique for precise local
mapping of primary malignant salivary tumours. Although new
developments such as diffusion (DWI/ADC) and perfusion (DCE-
MRI/IVIM) MRI suggest better differentiation among tumour types,
the reported numbers are too low to draw firm conclusions. Addi-
tional US with FNAC is recommended for assessing the nature of a
primary salivary gland tumour and N-staging the neck in all
patients.
For the assessment of distant metastases at initial presentation
18FDG PET/CT seems to be the most sensitive imaging technique.
However, because most distant metastases do occur in the lungs,
chest-CT may be considered. After completion of treatment, a
base-line MRI of the head and neck is recommended in patients
with high-grade malignant tumours in whom local recurrence
rates are high. In patients with loco-regional recurrent disease,
MRI, if possible combined with US-guided FNAC, is the preferred
imaging technique to direct treatment strategies. In case of distant
metastases during follow-up, chest-CT or symptom-related imag-
ing is recommended. MRI of the head and neck in combination
with CECT of the chest and abdomen plays an important role for
evaluation of experimental chemotherapy in patients with
advanced primary salivary gland tumours or recurrent disease.
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